Abstract

In 2006, the first of two vaccines for human papillomavirus (HPV) prevention, Gardasil™, was approved for use in Canada. Gardasil™, produced by Merck Frosst Canada Ltd, is a quadrivalent vaccine product against HPV 6, 11, 16 and 18. The National Advisory Committee on Immunization (NACI) statement on the recommendations for the use of HPV vaccine for the prevention of cervical cancer was released in January 2007. A second HPV candidate vaccine, Cervarix™, produced by GlaxoSmithKline (GSK) Inc in Belgium is currently undergoing the regulatory review process by Health Canada. This is a bivalent vaccine against HPV 16 and 18. A need for a systematic literature review on the characteristics of the HPV vaccines was identified. This review was commissioned by the Public Health Agency of Canada (PHAC). The purpose of this document is to apply the Erickson, De Wals and Farand framework on immunization programs to review the following: the disease burden attributed to HPV 6, 11, 16, and 18; and to identify non-HPV risk factors for cervical cancer; and the vaccine characteristics of Gardasil™ and Cervarix™. Source: http://www.phac-aspc.gc.ca/naci-ccni/lr-sl_2-eng.php

Americas Canada epidemiology health policy Human papillomavirus (HPV)